Ten-year Survival in Glioblastoma. A Systematic Review
Overview
Authors
Affiliations
Glioblastoma (GBM) is among the most deadly neoplasms associated with one of the worst 5-year overall survival (OS) rates among all human cancers. The aim of this systematic review is to present all cases with OS of a decade or more and to perform a descriptive analysis of the group. This systematic review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A comprehensive search for relevant articles was performed on PubMed, Embase and Google Scholar for a period until June 10, 2016, using the following search words: glioblastoma multiforme, glioblastoma, GBM, long-term survival/survivors. Reports containing cases with the long-term survival of 10 years or longer were included in the review. The search produced 36 studies with 162 cases published in the years 1950-2014. The rate of long survivors in the cohort studied was established 0.76%. Mean age at diagnosis, OS and PFS were 31.1 ± 11.1, 15.9 ± 6.3, 11.9 ± 5.6 years respectively. Total and subtotal resections were found in 82 and 58 patients respectively. Nine cases received a biopsy alone. No statistical differences were found in a comparison of PFS, OS and age between total and subtotal resection groups. A regression analysis showed a significant correlation between PFS and OS, with an inverse relationship stated between age at diagnosis and OS. The 10-year survival rate in the cohort studied with GBM was estimated 0.71%. OS was positively correlated with the length of PFS and inversely related with age at diagnosis.
Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma.
Sears T, Wang W, Drumm M, Unruh D, McCord M, Horbinski C Cancers (Basel). 2025; 17(5).
PMID: 40075681 PMC: 11898980. DOI: 10.3390/cancers17050834.
Torres-Tenor J, Garcia-Leal A, Hui D, Bruera E, Martinez-Marin V, Castano-Cantos A J Neurooncol. 2025; .
PMID: 40048038 DOI: 10.1007/s11060-025-04993-3.
Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.
PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.
de Godoy L, Rajan A, Banihashemi A, Patel T, Desai A, Bagley S Brain Sci. 2025; 15(2).
PMID: 40002479 PMC: 11852837. DOI: 10.3390/brainsci15020146.
Innovative perspectives on glioblastoma: the emerging role of long non-coding RNAs.
Doghish A, Mahmoud A, Abd-Elmawla M, Zaki M, Aborehab N, Hatawsh A Funct Integr Genomics. 2025; 25(1):43.
PMID: 39992471 DOI: 10.1007/s10142-025-01557-6.